These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12028054)

  • 1. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major.
    Li CK; Chan PK; Ling SC; Ha SY
    Br J Haematol; 2002 Jun; 117(3):755-8. PubMed ID: 12028054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with interferon and ribavirin for chronic hepatitis C infection in beta-thalassaemia major.
    Saffar MJ; Saffar H; Khalilian AR; Naqshvar F
    East Mediterr Health J; 2009; 15(4):785-91. PubMed ID: 20187529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection.
    Inati A; Taher A; Ghorra S; Koussa S; Taha M; Aoun E; Sharara AI
    Br J Haematol; 2005 Aug; 130(4):644-6. PubMed ID: 16098081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-co-infected non-responder to standard interferon-based.
    Hamidah A; Thambidorai CR; Jamal R
    Med J Malaysia; 2005 Oct; 60(4):517-9. PubMed ID: 16570722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
    Zhou YQ; Wang XH; Hong GH; Zhu Y; Zhang XQ; Hu YJ; Mao Q
    J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of interferon and ribavirin combination therapy in sixty-two patients with chronic hepatitis C originating from a single blood donor].
    Liu SD; Cheng ML; Ren H; Yang QK; Shu DY
    Zhonghua Gan Zang Bing Za Zhi; 2012 Aug; 20(8):589-92. PubMed ID: 23207152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin.
    Fung J; Lai CL; Hung I; Young J; Cheng C; Wong D; Yuen MF
    J Infect Dis; 2008 Sep; 198(6):808-12. PubMed ID: 18657036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic hepatitis C virus infection with interferon alfa and ribavirin: sustained response in two patients with transfusion dependent thalassaemia.
    Hamidah A; Yong JF; Zulkifli HI; Jamal R
    Med J Malaysia; 2002 Sep; 57(3):353-6. PubMed ID: 12440276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.
    Hui CK; Yuen MF; Sablon E; Chan AO; Wong BC; Lai CL
    J Infect Dis; 2003 Apr; 187(7):1071-4. PubMed ID: 12660921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.
    el-Zayadi A; Selim O; Haddad S; Simmonds P; Hamdy H; Badran HM; Shawky S
    Ital J Gastroenterol Hepatol; 1999; 31(6):472-5. PubMed ID: 10575565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
    Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
    Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
    Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection.
    Lee CM; Kee KM; Hung CH; Eng HL; Chang CH; Huang CM; Wang JH; Hu TH; Lu SN; Changchien CS; Chen WJ
    Antivir Ther; 2006; 11(1):17-23. PubMed ID: 16518956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.
    Arase Y; Suzuki F; Akuta N; Sezaki H; Suzuki Y; Kawamura Y; Kobayashi M; Hosaka T; Yatsuji H; Hirakawa M; Saito S; Ikeda K; Kobayashi M; Kumada H
    Intern Med; 2009; 48(5):253-8. PubMed ID: 19252344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
    New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting.
    Desmond CP; Roberts SK; Dudley F; Mitchell J; Day C; Nguyen S; Pianko S
    J Viral Hepat; 2006 May; 13(5):311-5. PubMed ID: 16637861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.